CorMedix Inc. (CRMD)
NASDAQ: CRMD · Real-Time Price · USD
7.77
+0.08 (1.04%)
At close: Sep 24, 2026, 4:00 PM EDT
7.77
0.00 (0.00%)
After-hours: Sep 24, 2026, 6:27 PM EDT
CorMedix Employees
CorMedix had 191 employees as of December 31, 2025. The number of employees increased by 126 or 193.85% compared to the previous year.
Employees
191
Change (1Y)
126
Growth (1Y)
193.85%
Revenue / Employee
$2,420,152
Profits / Employee
$973,901
Market Cap
605.63M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 191 | 126 | 193.85% | 191 | 0 |
| Dec 31, 2024 | 65 | -18 | -21.69% | 64 | 1 |
| Dec 31, 2023 | 83 | 42 | 102.44% | 82 | 1 |
| Dec 31, 2022 | 41 | 11 | 36.67% | 40 | 1 |
| Dec 31, 2021 | 30 | -5 | -14.29% | 29 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Valneva SE | 620 |
| Ginkgo Bioworks Holdings | 485 |
| Phathom Pharmaceuticals | 371 |
| Allogene Therapeutics | 152 |
| Prime Medicine | 146 |
| MapLight Therapeutics | 133 |
| CytomX Therapeutics | 69 |
| AgomAb Therapeutics NV | 62 |
CRMD News
- 1 day ago - CorMedix initiated with an Outperform at Oppenheimer - TheFly
- 15 days ago - CorMedix Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 15 days ago - CorMedix Slides: Corporate presentation - Filings
- 23 days ago - CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference - GlobeNewsWire
- 5 weeks ago - CorMedix reports Q2 EPS 29c vs. 28c last year - TheFly
- 6 weeks ago - CorMedix Earnings Call Transcript: Q2 2026 - Transcripts
- 6 weeks ago - CorMedix Earnings release: Q2 2026 - Filings
- 6 weeks ago - CorMedix Quarterly report: Q2 2026 - Filings